PharmaCyte Biotech Inc (PMCB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PharmaCyte Biotech Inc (PMCB) has a cash flow conversion efficiency ratio of -0.020x as of January 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-786.85K) by net assets ($39.40 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PharmaCyte Biotech Inc (PMCB) liquidity interval to measure how many days the company can operate on defensive assets alone.
PharmaCyte Biotech Inc - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how PharmaCyte Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
PharmaCyte Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PharmaCyte Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
JPMorgan Euro Small Companies Trust Plc
LSE:JEDT
|
0.026x |
|
Crédito Real S.A.B. de C.V. Sociedad Financiera de Objeto Múltiple Entidad No Regulada
MX:CREAL
|
-0.018x |
|
2020 Bulkers Ltd.
F:0FF
|
0.104x |
|
DXN Ltd
AU:DXN
|
-0.368x |
|
Agri-Tech (India) Limited
NSE:AGRITECH
|
-0.010x |
|
Tempo Inti Media Tbk
JK:TMPO
|
-0.034x |
|
Hemostemix Inc
V:HEM
|
0.839x |
|
Worksport Ltd
NASDAQ:WKSP
|
-0.412x |
Annual Cash Flow Conversion Efficiency for PharmaCyte Biotech Inc (2004–2025)
The table below shows the annual cash flow conversion efficiency of PharmaCyte Biotech Inc from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see PMCB stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-04-30 | $51.89 Million | $-2.98 Million | -0.057x | -5.41% |
| 2024-04-30 | $39.51 Million | $-2.15 Million | -0.054x | -4.32% |
| 2023-04-30 | $72.69 Million | $-3.79 Million | -0.052x | -13.98% |
| 2022-04-30 | $89.92 Million | $-4.12 Million | -0.046x | +90.82% |
| 2021-04-30 | $6.68 Million | $-3.33 Million | -0.499x | -8.53% |
| 2020-04-30 | $5.09 Million | $-2.34 Million | -0.459x | +19.54% |
| 2019-04-30 | $5.04 Million | $-2.88 Million | -0.571x | +35.14% |
| 2018-04-30 | $5.77 Million | $-5.08 Million | -0.881x | -113.24% |
| 2017-04-30 | $8.09 Million | $-3.34 Million | -0.413x | +38.03% |
| 2016-04-30 | $6.52 Million | $-4.35 Million | -0.666x | +13.26% |
| 2015-04-30 | $5.94 Million | $-4.56 Million | -0.768x | -339.64% |
| 2014-04-30 | $8.94 Million | $-1.56 Million | -0.175x | -141.24% |
| 2013-04-30 | $-921.46K | $-390.43K | 0.424x | +272.55% |
| 2012-04-30 | $-2.28 Million | $-259.29K | 0.114x | +37.82% |
| 2011-04-30 | $-2.73 Million | $-225.23K | 0.083x | -83.47% |
| 2010-04-30 | $-1.95 Million | $-974.06K | 0.499x | +268.02% |
| 2009-04-30 | $3.99 Million | $-1.19 Million | -0.297x | -85.49% |
| 2008-04-30 | $7.44 Million | $-1.19 Million | -0.160x | -95.28% |
| 2007-04-30 | $4.29 Million | $-351.60K | -0.082x | +66.25% |
| 2006-04-30 | $4.41 Million | $-1.07 Million | -0.243x | -111.25% |
| 2005-04-30 | $-1.30 Million | $-2.80 Million | 2.160x | +49.95% |
| 2004-04-30 | $-153.43K | $-221.03K | 1.441x | -- |
About PharmaCyte Biotech Inc
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including adv… Read more